In the last reported quarter, the company registered an earnings surprise of 109.09%. PEN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 109.42%. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has remained constant at $1. Penumbra’s stock has risen 175.8% in the past year. You can see the complete list of today’s Zacks #1 Rank stocks here. While Penumbra and Lantheus each sport a Zacks Rank #1 (Strong Buy), Haemonetics carries a Zacks Rank #2 (Buy) at present.
RATINGS OF DNA DIAGNOSTICS CENTER FREE
Some better-ranked stocks in the overall healthcare sector are Penumbra ( PEN Quick Quote PEN - Free Report), Lantheus ( LNTH Quick Quote LNTH - Free Report) and Haemonetics ( HAE Quick Quote HAE - Free Report). Myriad Genetics currently carries a Zacks Rank #3 (Hold). In the past six months, MYGN shares have increased 35.2% against the industry’s fall of 11.6%. The NYS certification strengthens the advancement of precision medicines by increasing access to genetic testing, which can help patients with cancer and their providers determine more targeted treatment decisions. The new biomarker adds another companion diagnostic option for providers to help guide treatment decisions for patients with ovarian cancer.Įarlier in April, Myriad Genetics and Intermountain Precision Genomics, a service of Intermountain Health, received the New York State Clinical Laboratory Permit to offer solid tumor testing to patients in all 50 U.S. In May 2023, Myriad Genetics announced the addition of Folate Receptor Alpha to its Precise Oncology Solutions portfolio. The growing incidences of acquired cystic kidney disease and hepatitis C increases the risk of RCC, thereby boosting the market’s growth rate. With cancer being the greatest cause of mortality worldwide, RCC is one of the most rapidly growing solid tumor cancers. Per a Research report, the global renal cell carcinoma market was valued at $635.4 million in 2021 and is expected to witness a CAGR of 5.9% by 2029. This is a significant development because most currently available MRD tests monitor 50 or fewer variants from the tumor. Per a representative at MYGN, the MRD assay will be more sensitive in RCC, given that it tracks up to thousands of variants identified by sequencing the tumor's whole genome. The research team at the Cancer Center will investigate the use of Myriad’s MRD testing platform as a non-invasive tool to inform treatment selection, surveillance and radiotherapy treatment response in individuals with metastatic RCC. The joint efforts of Myriad and MD Anderson are set to determine if patients with RCC will benefit from a comprehensive genome-wide approach to MRD with this platform. MRD tests based on the exome sequencing of the tumor may not track enough variants to be adequately sensitive.
Significance of the MRD TestĪt present, there is a lack of non-invasive testing platforms available for RCC. The MRD test can be used to monitor ctDNA levels during both treatment and surveillance following diagnosis. The latest project will utilize MYGN’s minimal residual disease (MRD) testing platform, a tumor-informed high-definition assay that detects circulating tumor DNA (ctDNA). Through the collaboration, Myriad will support MD Anderson researchers studying metastatic renal cell carcinoma (RCC) treatment selection and response.
The company was itself acquired by private equity firm GHO Capital in October 2015 for €104 million ($118 million).Myriad Genetics ( MYGN Quick Quote MYGN - Free Report) recently entered into a research agreement with The University of Texas MD Anderson Cancer Center. "We see the opportunity for significant growth of DNA testing services in the greater South Florida region," said DNA Diagnostics President and CEO Connie Hallquist in a statement.ĭNA Diagnostics, which is based in Ohio and the UK, added that this is the first of what are expected to be several acquisitions of regional DNA testing services providers.
Under the terms of the deal, DNA Diagnostics will acquire all of All About Truth's assets, including its existing physical plant and equipment, and will retain existing employees. NEW YORK (GenomeWeb) – DNA testing services provider DNA Diagnostics Center announced that it has acquired All About Truth DNA Services, a provider of DNA testing based in Plantation, Florida.Īll About Truth specializes in AABB-certified immigration DNA testing, biological family relationship DNA testing, prenatal DNA testing, and forensic DNA testing.
0 kommentar(er)
